Cargando…
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, i...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831597/ https://www.ncbi.nlm.nih.gov/pubmed/35145071 http://dx.doi.org/10.1038/s41408-022-00624-6 |
_version_ | 1784648540459368448 |
---|---|
author | Dispenzieri, Angela Krishnan, Amrita Arendt, Bonnie Blackwell, Beth Wallace, Paul K. Dasari, Surendra Vogl, Dan T. Efebera, Yvonne Fei, Mingwei Geller, Nancy Giralt, Sergio Hahn, Theresa Howard, Alan Kohlhagen, Mindy Landau, Heather Hari, Parameswaran Pasquini, Marcelo C. Qazilbash, Muzaffar H. McCarthy, Philip Shah, Nina Vesole, David H. Stadtmauer, Edward Murray, David |
author_facet | Dispenzieri, Angela Krishnan, Amrita Arendt, Bonnie Blackwell, Beth Wallace, Paul K. Dasari, Surendra Vogl, Dan T. Efebera, Yvonne Fei, Mingwei Geller, Nancy Giralt, Sergio Hahn, Theresa Howard, Alan Kohlhagen, Mindy Landau, Heather Hari, Parameswaran Pasquini, Marcelo C. Qazilbash, Muzaffar H. McCarthy, Philip Shah, Nina Vesole, David H. Stadtmauer, Edward Murray, David |
author_sort | Dispenzieri, Angela |
collection | PubMed |
description | Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response. |
format | Online Article Text |
id | pubmed-8831597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-88315972022-02-24 Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) Dispenzieri, Angela Krishnan, Amrita Arendt, Bonnie Blackwell, Beth Wallace, Paul K. Dasari, Surendra Vogl, Dan T. Efebera, Yvonne Fei, Mingwei Geller, Nancy Giralt, Sergio Hahn, Theresa Howard, Alan Kohlhagen, Mindy Landau, Heather Hari, Parameswaran Pasquini, Marcelo C. Qazilbash, Muzaffar H. McCarthy, Philip Shah, Nina Vesole, David H. Stadtmauer, Edward Murray, David Blood Cancer J Article Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response. Nature Publishing Group UK 2022-02-10 /pmc/articles/PMC8831597/ /pubmed/35145071 http://dx.doi.org/10.1038/s41408-022-00624-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Dispenzieri, Angela Krishnan, Amrita Arendt, Bonnie Blackwell, Beth Wallace, Paul K. Dasari, Surendra Vogl, Dan T. Efebera, Yvonne Fei, Mingwei Geller, Nancy Giralt, Sergio Hahn, Theresa Howard, Alan Kohlhagen, Mindy Landau, Heather Hari, Parameswaran Pasquini, Marcelo C. Qazilbash, Muzaffar H. McCarthy, Philip Shah, Nina Vesole, David H. Stadtmauer, Edward Murray, David Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) |
title | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) |
title_full | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) |
title_fullStr | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) |
title_full_unstemmed | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) |
title_short | Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT) |
title_sort | mass-fix better predicts for pfs and os than standard methods among multiple myeloma patients participating on the stamina trial (bmt ctn 0702 /07lt) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8831597/ https://www.ncbi.nlm.nih.gov/pubmed/35145071 http://dx.doi.org/10.1038/s41408-022-00624-6 |
work_keys_str_mv | AT dispenzieriangela massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT krishnanamrita massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT arendtbonnie massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT blackwellbeth massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT wallacepaulk massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT dasarisurendra massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT vogldant massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT efeberayvonne massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT feimingwei massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT gellernancy massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT giraltsergio massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT hahntheresa massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT howardalan massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT kohlhagenmindy massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT landauheather massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT hariparameswaran massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT pasquinimarceloc massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT qazilbashmuzaffarh massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT mccarthyphilip massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT shahnina massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT vesoledavidh massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT stadtmaueredward massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt AT murraydavid massfixbetterpredictsforpfsandosthanstandardmethodsamongmultiplemyelomapatientsparticipatingonthestaminatrialbmtctn070207lt |